Rockefeller Capital Management
GSK icon

Rockefeller Capital Management’s GSK GSK Stock Holding History

Rockefeller Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.11M Buy
128,795
+12,547
+11% +$680K 0.01% 790
2025
Q4 		$5.7M Buy
116,248
+39,140
+51% +$1.83M 0.01% 836
2025
Q3 		$3.33M Sell
77,108
-3,312
-4% -$129K 0.01% 965
2025
Q2 		$3.09M Sell
80,420
-167,059
-68% -$6.38M 0.01% 946
2025
Q1 		$9.59M Sell
247,479
-88,352
-26% -$3.23M 0.02% 577
2024
Q4 		$11.4M Sell
335,831
-23,398
-7% -$842K 0.03% 520
2024
Q3 		$14.7M Sell
359,229
-2,006
-0.6% -$82.1K 0.04% 427
2024
Q2 		$13.9M Buy
361,235
+10,182
+3% +$428K 0.04% 414
2024
Q1 		$15M Sell
351,053
-9,719
-3% -$401K 0.04% 401
2023
Q4 		$13.4M Sell
360,772
-150,471
-29% -$5.4M 0.04% 382
2023
Q3 		$18.5M Buy
511,243
+80,919
+19% +$2.87M 0.07% 277
2023
Q2 		$15.3M Buy
430,324
+38,378
+10% +$1.38M 0.06% 339
2023
Q1 		$13.9M Sell
391,946
-57,026
-13% -$2M 0.06% 349
2022
Q4 		$15.8M Buy
448,972
+28,093
+7% +$936K 0.08% 274
2022
Q3 		$12.4M Buy
420,879
+128,179
+44% +$4.86M 0.06% 303
2022
Q2 		$15.9M Buy
292,700
+94,497
+48% +$5.22M 0.08% 244
2022
Q1 		$10.8M Buy
198,203
+9,901
+5% +$538K 0.05% 343
2021
Q4 		$10.4M Buy
188,302
+19,256
+11% +$1M 0.05% 343
2021
Q3 		$8.07M Buy
169,046
+17,742
+12% +$891K 0.04% 354
2021
Q2 		$7.53M Buy
151,304
+43,570
+40% +$2.09M 0.04% 349
2021
Q1 		$4.8M Buy
107,734
+8,864
+9% +$402K 0.03% 379
2020
Q4 		$4.55M Sell
98,870
-2,149,552
-96% -$98.7M 0.03% 344
2020
Q3 		$106M Sell
2,248,422
-8,881
-0.4% -$445K 0.99% 16
2020
Q2 		$115M Sell
2,257,303
-798,200
-26% -$41M 1.2% 13
2020
Q1 		$145M Buy
3,055,503
+3,035,456
+15,142% +$162M 1.9% 10
2019
Q4 		$1.18M Buy
20,047
+746
+4% +$41.5K 0.01% 422
2019
Q3 		$1.03M Buy
19,301
+1,229
+7% +$63.2K 0.01% 385
2019
Q2 		$904K Buy
18,072
+10,922
+153% +$548K 0.01% 355
2019
Q1 		$373K Buy
+7,150
New +$357K 0.01% 517

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Rockefeller Capital Management's GSK Position: Q1 2026 in Review

Rockefeller Capital Management increased its GSK (GSK) stake by 11% in Q1 2026, buying an estimated $680K and bringing the position to 128,795 shares worth $7.11M. The position accounts for 0.01% of the portfolio, ranked #790.

Rockefeller Capital Management first reported a position in GSK in Q1 2019 and has held it in 29 quarters since. The position peaked at $145M in Q1 2020. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Rockefeller Capital Management held 128,795 shares of GSK worth $7.11M as of Q1 2026.
  • Rockefeller Capital Management bought 12,547 GSK shares in Q1 2026, an estimated $680K.
  • GSK made up 0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #790 holding.
  • Rockefeller Capital Management first reported a position in GSK in Q1 2019 and has held it in 29 quarters since.
  • Rockefeller Capital Management's GSK position peaked at $145M in Q1 2020.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.